Coherus Oncology Statistics
Total Valuation
CHRS has a market cap or net worth of $217.85 million. The enterprise value is $166.72 million.
| Market Cap | 217.85M |
| Enterprise Value | 166.72M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 154.50 million shares outstanding. The number of shares has increased by 14.13% in one year.
| Current Share Class | 154.50M |
| Shares Outstanding | 154.50M |
| Shares Change (YoY) | +14.13% |
| Shares Change (QoQ) | +13.50% |
| Owned by Insiders (%) | 12.21% |
| Owned by Institutions (%) | 42.71% |
| Float | 135.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.28 |
| Forward PS | 2.72 |
| PB Ratio | 3.58 |
| P/TBV Ratio | 13.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.89.
| Current Ratio | 1.77 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.95 |
Financial Efficiency
Return on equity (ROE) is -178.39% and return on invested capital (ROIC) is -324.31%.
| Return on Equity (ROE) | -178.39% |
| Return on Assets (ROA) | -30.52% |
| Return on Invested Capital (ROIC) | -324.31% |
| Return on Capital Employed (ROCE) | -133.13% |
| Weighted Average Cost of Capital (WACC) | 10.21% |
| Revenue Per Employee | $353,722 |
| Profits Per Employee | -$917,583 |
| Employee Count | 144 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 3.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.68% in the last 52 weeks. The beta is 0.95, so CHRS's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | +23.68% |
| 50-Day Moving Average | 1.41 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 53.35 |
| Average Volume (20 Days) | 1,345,519 |
Short Selling Information
The latest short interest is 24.00 million, so 15.53% of the outstanding shares have been sold short.
| Short Interest | 24.00M |
| Short Previous Month | 24.53M |
| Short % of Shares Out | 15.53% |
| Short % of Float | 17.70% |
| Short Ratio (days to cover) | 30.63 |
Income Statement
In the last 12 months, CHRS had revenue of $50.94 million and -$132.13 million in losses. Loss per share was -$1.00.
| Revenue | 50.94M |
| Gross Profit | 35.12M |
| Operating Income | -154.00M |
| Pretax Income | -161.15M |
| Net Income | -132.13M |
| EBITDA | -150.39M |
| EBIT | -154.00M |
| Loss Per Share | -$1.00 |
Balance Sheet
The company has $105.31 million in cash and $54.18 million in debt, with a net cash position of $51.13 million or $0.33 per share.
| Cash & Cash Equivalents | 105.31M |
| Total Debt | 54.18M |
| Net Cash | 51.13M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 60.84M |
| Book Value Per Share | 0.39 |
| Working Capital | 58.28M |
Cash Flow
| Operating Cash Flow | -186.03M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.61M |
| Net Borrowing | -121,000 |
| Free Cash Flow | -186.03M |
| FCF Per Share | -$1.20 |
Margins
Gross margin is 68.96%, with operating and profit margins of -302.33% and -259.41%.
| Gross Margin | 68.96% |
| Operating Margin | -302.33% |
| Pretax Margin | -316.37% |
| Profit Margin | -259.41% |
| EBITDA Margin | -295.25% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.13% |
| Shareholder Yield | -14.13% |
| Earnings Yield | -60.65% |
| FCF Yield | -85.40% |
Analyst Forecast
The average price target for CHRS is $7.75, which is 449.65% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.75 |
| Price Target Difference | 449.65% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 58.46% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHRS has an Altman Z-Score of -11.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.68 |
| Piotroski F-Score | 3 |